**IN18-02**

| **#** | **Variable** | **Description** | **Type** | **Value** | **Label** |
| --- | --- | --- | --- | --- | --- |
| 1 | **cytogene** | Cytogenetic score | Categorical | 0 | Unknown |
|  |  |  |  | 1 | Normal |
|  |  |  |  | 2 | Favorable |
|  |  |  |  | 3 | Intermediate |
|  |  |  |  | 4 | Poor |
|  |  |  |  | 5 | Other |
|  |  |  |  | 10 | Not tested/missing |
|  |  |  |  | 11 | MDS, N/A |
|  |  |  |  | 999 | Cytogenetics for AML/ALL |
| 2 | **disease** |  | Categorical | 10 | AML |
|  |  |  |  | 20 | ALL |
|  |  |  |  | 50 | MDS |
| 3 | **yeartx** | TX year | Continuous |  |  |
| 4 | **sex** | Gender  | Categorical | 1 | Male |
|  |  |  |  | 2 | Female |
|  |  |  |  | 3 | NA, non-resident of USA |
|  |  |  |  | 8 | Unknown |
|  |  |  |  | 9 | Not Answer |
| 5 | **systebac** | Systemic antibacterial antibiotics | Categorical | 1 | Yes |
|  |  |  |  | 2 | No |
|  |  |  |  | . | Missing |
| 6 | **antib\_fluo** | Type of Antibacterial prophylaxis | Categorical | 1 | Fluoroquinolone |
|  |  |  |  | 2 | Non-Fluroquinolone |
|  |  |  |  | 3 | Missing |
|  |  |  |  | 4 | NA [pre-2017] |
| 7 | **age** | Patient age | Continuous |  |  |
| 8 | **graftype** | Graft type in merge | Categorical | 1 | Bone marrow |
|  |  |  |  | 22 | Peripheral blood |
|  |  |  |  | 23 | Umbilical cord blood |
| 9 | **donorgp2** | Donor/recipient HLA match | Categorical | 0.1 | Cord blood-double |
|  |  |  |  | 0.2 | Cord blood-single |
|  |  |  |  | 1 | HLA-identical siblings |
|  |  |  |  | 2 | Twin |
|  |  |  |  | 3 | matched related |
|  |  |  |  | 4 | Mismatched related |
|  |  |  |  | 4.1 | Mismatched related, mismatch=1 |
|  |  |  |  | 4.2 | Mismatched related, mismatch>=2 |
|  |  |  |  | 4.3 | Mismatched related, mismatch missing |
|  |  |  |  | 5 | 8/8 unrelated |
|  |  |  |  | 6 | 7/8 unrelated |
|  |  |  |  | 7 | Multi donor(other than cord blood) |
|  |  |  |  | 8 | <=6/8 unrelated |
|  |  |  |  | 9 | Unrelated (HLA match information missing) |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | Donor/recipient HLA match |
| 10 | **agegp** | Age at transplant | Categorical | 1 | <12 |
|  |  |  |  | 2 | 12-17 |
|  |  |  |  | 3 | 18-39 |
|  |  |  |  | 4 | 40-64 |
|  |  |  |  | 5 | >=65 |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | Age at transplant, years |
| 11 | **obesity** | BMI |  | 1 | <18.5 |
|  |  |  |  | 2 | 18.5 – 24.9 |
|  |  |  |  | 3 | 25 – 29.9 |
|  |  |  |  | 4 | 30 – 34.9 |
|  |  |  |  | 5 | >=35 |
|  |  |  |  | 99 | Missing  |
| 12 | **kps** | Karnofsky/Lansky performance pre-Preparative Regimen | Categorical | 1 | <80 |
|  |  |  |  | 2 | 80-89 |
|  |  |  |  | 3 | >=90 |
|  |  |  |  | 999 | Karnofsky performance pre-Preparative Regimen |
| 13 | **lpamgp** | Conditioning Regimen containing Melphalan |  | 1 | Yes |
|  |  |  |  | 0 | No |
| 14 | **ethgp** | Race/Ethnicity | Categorical | 1 | Caucasian, non-Hispanic |
|  |  |  |  | 2 | African-American, non-Hispanic |
|  |  |  |  | 3 | Asian, non-Hispanic |
|  |  |  |  | 4 | Pacific islander, non-Hispanic |
|  |  |  |  | 5 | Native American, non-Hispanic |
|  |  |  |  | 41 | Hispanic, Caucasian |
|  |  |  |  | 42 | Hispanic, African-American |
|  |  |  |  | 43 | Hispanic, Asian |
|  |  |  |  | 44 | Hispanic, Parcific islander |
|  |  |  |  | 45 | Hispanic, Native American |
|  |  |  |  | 48 | Hispanic, more than one race |
|  |  |  |  | 49 | Hispanic, race unknown |
|  |  |  |  | 90 | Other |
|  |  |  |  | 99 | Missing |
| 15 | **sexmatch** | Donor/recipient gender match | Categorical | 1 | Male-Male |
|  |  |  |  | 2 | Male-Female |
|  |  |  |  | 3 | Female-Male |
|  |  |  |  | 4 | Female-Female |
|  |  |  |  | 5 | ?-Male |
|  |  |  |  | 6 | ?-Female |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | Donor/recipient gender match |
| 16 | **cmvmatch** | Donor/Recipient CMV status | Categorical | 0 | Cord Blood |
|  |  |  |  | 1 | +/+ |
|  |  |  |  | 2 | +/- |
|  |  |  |  | 3 | -/+ |
|  |  |  |  | 4 | -/- |
|  |  |  |  | 5 | +/? |
|  |  |  |  | 6 | -/? |
|  |  |  |  | 7 | ?/+ |
|  |  |  |  | 8 | ?/- |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | Donor/Recipient CMV status |
| 17 | **intxdx** | Time from diagnosis to transplant | Continuous |  |  |
| 18 | **intxdxgp** | Time from diagnosis to transplant | Categorical | 1 | <6 months’ |
|  |  |  |  | 2 | 6 month-1Y’ |
|  |  |  |  | 3 | 1Y-2Y |
|  |  |  |  | 4 | >=2Y |
|  |  |  |  | 999 | Time from diagnosis to transplant’ |
| 19 | **distage** | Disease status at HCT | Categorical | 1 | AML/ALL, early |
|  |  |  |  | 2 | AML/ALL, intermediate |
|  |  |  |  | 3 | AML/ALL, advanced |
|  |  |  |  | 4 | AML/ALL, unknown |
|  |  |  |  | 9 | MDS, early |
|  |  |  |  | 10 | MDS, advanced |
|  |  |  |  | 11 | MDS, unknown |
| 20 | **hctcigp2** | HCT-CI | Categorical | 0 | 0 |
|  |  |  |  | 1 | 1-2 |
|  |  |  |  | 2 | 3-4 |
|  |  |  |  | 3 | 5+ |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | HCT-CI |
| 21 | **condint3** | Conditioning regimen intensity | Categorical | 1 | Myeloablative with TBI |
|  |  |  |  | 2 | Myeloablative chemotherapy only |
|  |  |  |  | 3 | RIC/NMA |
| 22 | **ipssrpr** | IPSS-R prior to HCT (MDS only) | Categorical | 1 | Very low |
|  |  |  |  | 2 | Low |
|  |  |  |  | 3 | Intermediate |
|  |  |  |  | 4 | High |
|  |  |  |  | 5 | Very high |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 100 | AML/ALL N/A |
|  |  |  |  | 999 | IPSSr prior to transplant (MDS only) |
| 23 | **atgcampathgp** | ATG/Campath | Categorical | 1 | ATG + Alemtuzumab |
|  |  |  |  | 2 | ATG alone |
|  |  |  |  | 3 | Alemtuzumab alone |
|  |  |  |  | 4 | No ATG or Alemtuzumab |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | ATG/Alemtuzumab |
| 24 | **agvhd24** | Grade 2-4 acute GVHD | Categorical | 0 | No |
|  |  |  |  | 1 | Yes |
| 25 | **gvhdgp2** | GVHD prophylaxis | Categorical | 0 | No GVHD prophylaxis (forms under review) |
|  |  |  |  | 1 | Ex vivo T-cell depletion |
|  |  |  |  | 2 | CD34 selection |
|  |  |  |  | 3.1 | Post-CY + other(s) |
|  |  |  |  | 3.2 | Post-CY alone |
|  |  |  |  | 4 | TAC/CSA + MMF +- others |
|  |  |  |  | 5 | TAC/CSA + MTX +- others |
|  |  |  |  | 6 | TAC/CSA + others (except MTX, MMF) |
|  |  |  |  | 7 | TAC/CSA alone |
|  |  |  |  | 8 | MMF +/- Other |
|  |  |  |  | 9 | MTX +/- Other |
|  |  |  |  | 12 | SIRO +/- others (Not TAC/CSA) |
|  |  |  |  | 13 | ATG/CAMPATH alone |
|  |  |  |  | 14 | Steroids alone |
|  |  |  |  | 20 | Other GVHD prophylaxis |
|  |  |  |  | 999 | GVHD prophylaxis |
| 26 | **anc500** | Neutrophil engraftment | Categorical | 1 | Yes |
|  |  |  |  | 2 | No |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | Neutrophil engraftment |
| 27 | **intx\_anc** | Time from transplant to ANC>500, days | Continuous |  |  |
| 28 | **intxagvhd24\_d** | Time from transplant to aGVHD, days | Continuous |  |  |
| 29 | **plat** | Platelet engraftment | Categorical | 1 | Yes |
|  |  |  |  | 2 | No |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | Platelet engraftment |
| 30 | **intx\_pla20** | Time from transplant to platelet>=20K | Continuous |  |  |
| 31 | **intx\_cdi100** | Time from transplant to CDI, days | Continuous |  |  |
| 32 | **agvh\_cdi** | Acute GVHD grade II-IV occurring prior to CDI | Categorical | 1 | Yes |
|  |  |  |  | 2 | No |
|  |  |  |  | 3 | No GVHD2-4 |
|  |  |  |  | 4 | Has GVHD2-4, no DCI |
|  |  |  |  | 5 | No GVHD2-4, no DCI |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | Acute GVHD grade II-IV occurring prior to CDI |
| 33 | **agvh\_gi** | Lower GI acute GVHD stage 2 - 4 occurring prior to CDI | Categorical | 1 | Yes |
|  |  |  |  | 2 | No |
|  |  |  |  | 3 | No Lower GI GVHD2-4 |
|  |  |  |  | 4 | Has lower GI, no CDI |
|  |  |  |  | 5 | No lower GI, no CDI |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | Lower GI acute GVHD grade II-IV occurring prior to CDI |
| 34 | **flowgp** | Flow cytometry for MRD Analysis | Categorical | 1 | Yes |
|  |  |  |  | 2 | No |
|  |  |  |  | 99 | Missing |
|  |  |  |  | 999 | Flow cytometry |
|  |  |  |  | 999 | Systemic antibacterial prophylzxis given |
| 35 | **hospdayi** | Number of days in the hospital in first 100 days post-transplant | Continuous |  |  |
| 36 | **intxsurv** | Time from HCT to death/last follow-up date | Continuous |  |  |
| 37 | **dead** | Overall survival | Categorical | 0 | No |
|  |  |  |  | 1 | Yes |
| 38 | **cgvhd** | Chronic GVHD | Categorical | 0 | No |
|  |  |  |  | 1 | Yes |
| 39 | **intxagvhd24** | Time between transplant and 2-4 acute GVHD, months | Continuous |  |  |
| 40 | **intxcgvhd** | Time between transplant and chronic GVHD, months | Continuous |  |  |
| 41 | **rel** | Relapse | Categorical | 0 | No |
|  |  |  |  | 1 | Yes |
| 42 | **trm** | Treatment related mortality | Categorical | 0 | No |
|  |  |  |  | 1 | Yes |
| 43 | **dfs** | Disease free survival | Categorical | 0 | No |
|  |  |  |  | 1 | Yes |
| 44 | **cdi100** | Incidence of CDI within first 100 days | Continuous |  |  |
| 45 | **infec** | Infection-Related mortality (IRM) | Continuous |  |  |
| 46 | **intx\_infec** | Time from tx to Infection-Related mortality, month | Continuous |  |  |
| 47 | **agvhd24\_lg** | Lower GI stage 2 – 4 aGVHD | Continuous |  |  |
| 48 | **intxagvhd24\_lg** | Time between transplant and lower GI stage 2 – 4 aGVHD, months  | Continuous |  |  |
| 49 | **cgvhd\_gi** | GI cGVHD | Continuous |  |  |
| 50 | **intxcgvhd\_gi** | Time between transplant and GI cGVHD, months | Continuous |  |  |
| 51 | **intxrel\_d** | Time between transplant and relapse, days | Continuous |  |  |
| 52 | **dccn** | Dummy CCN | Continuous |  |  |
| 53 | **dcrid** | Dummy CRID | Continuous |  |  |
| 54 | **cdi\_recur** | recurrent CDI by 1 year | Categorical | 1 | Yes, recurrent CDI by 1 year |
|  |  |  |  | 2 | Yes CDI by 1 year but no recurrent |
|  |  |  |  | 3 | No CDI  |
| 55 | **mbicdigp** | MBI-BSI occurring ± 7 days of CDI | Categorical | 1 | Yes |
|  |  |  |  | 0 | No |
|  |  |  |  | . | Missing |
| 56 | **cmvcdigp** | CMV DNAemia/GI disease ± 14 days of CDI | Categorical | 1 | Yes |
|  |  |  |  | 0 | No |
|  |  |  |  | . | Missing |
| 57 | **vrecdigp** | VRE BSI occurring ± 7 days of CDI | Categorical | 1 | Yes |
|  |  |  |  | 0 | No |
|  |  |  |  | . | Missing |